Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | AKT2 | P31751 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715684 | 0.88 | LMNA (0.65) | PGRMEN1KMT2ALMNAHTT | |
| SCHEMBL7567421 | 0.88 | PGR (0.61) | PGRMEN1KMT2ALMNAHTT | |
| SCHEMBL16042879 | 0.85 | PGR (0.49) | PGRMEN1KMT2ALMNAHTT | |
| SCHEMBL18555401 | 0.84 | MEN1 (0.57) | PGRMEN1KMT2ALMNAHTT | |
| SCHEMBL7101724 | 0.82 | KMT2A (0.78) | MEN1KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL24728542 | 0.82 | PGR (0.61) | PGRMEN1KMT2ALMNAHTT | |
| SCHEMBL2762074 | 0.80 | LMNA (0.81) | PGRMEN1KMT2ALMNAHTT | |
| SCHEMBL22191016 | 0.80 | CYP1A2 (0.60) | PGRMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4629626 | 0.79 | B3GNT2 (0.47) | PGRMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3536483 | 0.78 | HDAC1 (0.70) | HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-6794373-B2 | ADMINISTERING TO A FEMALE OF CHILD BEARING AGE OVER A PERIOD OF 28 CONSECUTIVE DAYS A FIRST PHASE OF FROM 18 TO 21 DAILY DOSAGE UNITS OF A PROGESTATIONAL AGENT, AND A SECOND PHASE OF FROM 1 TO 7 DAILY DOSAGE UNITS OF AN ANTIPROGESTIN AGENT | WYETH | 2004-09-21 | — | — | US | disclosed |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | LIGAND PHARMACEUTICALS INCORPORATED | 2002-10-17 | — | — | US | disclosed |
| US-20020115853-A1 | Benzimidazolones and analogues | WYETH | 2002-08-22 | — | — | US | disclosed |
| US-6423699-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-23 | — | — | US | disclosed |
| US-6380235-B1 | USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-30 | — | — | US | disclosed |
| EP-1173213-A1 | COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066168-A1 | COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010556-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | PGR 3140/4885MEN1 2913/4885KMT2A 305/4885 |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PGR 3258/4885MEN1 3226/4885KMT2A 372/4885 |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | PGR, GNRHR, NR4A1 | PGR 1/4885MEN1 1372/4885KMT2A 984/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PGR 3258/4885MEN1 3226/4885KMT2A 372/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PGR 3258/4885MEN1 3226/4885KMT2A 372/4885 |
| US-20020115853-A1 | Benzimidazolones and analogues | PGR, NR5A1, NR3C2 | PGR 1/4885MEN1 3270/4885KMT2A 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.